Leerink initiates coverage on Pyxis with 'outperform'; shares rise

Pyxis Oncology

23/01/2024 12:22

** Shares of Pyxis Oncology  PYXS.O  rise 3.5% to $2.64
premarket
    ** Brokerage Leerink initiates PYXS with "outperform"
rating, price target at $12
    ** PT represents a more than four-fold upside to the stock's
last close
    ** Leerink believes that co's PYX-201 is a competitively
designed ADC that has the potential to be used across a range of
difficult-to-treat solid tumor types
    ** ADCs, or antibody-drug conjugates, are a class of
treatments often called "guided-missiles", that target specific
cancer antigens while not harming healthy cells
        ** All 5 brokerages rate the stock "buy" or higher;
their median PT is $6 - LSEG data
    ** Up to last close, stock up 62.4% in the last 12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))